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Abstract
There is growing interest in investigating the role of subtle changes in blood–brain barrier (BBB) function in common neurological
disorders and the possible use of imaging techniques to assess these abnormalities. Some studies have used dynamic contrast-enhanced MR
imaging (DCE-MRI) and these have demonstrated much smaller signal changes than obtained from more traditional applications of the
technique, such as in intracranial tumors and multiple sclerosis. In this work, preliminary results are presented from a DCE-MRI study of
patients with mild stroke classified according to the extent of visible underlying white matter abnormalities. These data are used to estimate
typical signal enhancement profiles in different tissue types and by degrees of white matter abnormality. The effect of scanner noise, drift and
different intrinsic tissue properties on signal enhancement data is also investigated and the likely implications for interpreting the
enhancement profiles are discussed. No significant differences in average signal enhancement or contrast agent concentration were observed
between patients with different degrees of white matter abnormality, although there was a trend towards greater signal enhancement with
more abnormal white matter. Furthermore, the results suggest that many of the factors considered introduce uncertainty of a similar
magnitude to expected effect sizes, making it unclear whether differences in signal enhancement are truly reflective of an underlying BBB
abnormality or due to an unrelated effect. As the ultimate aim is to achieve a reliable quantification of BBB function in subtle disorders, this
study highlights the factors which may influence signal enhancement and suggests that further work is required to address the challenging
problems of quantifying contrast agent concentration in healthy and diseased living human tissue and of establishing a suitable model to
enable quantification of relevant physiological parameters. Meanwhile, it is essential that future studies use an appropriate control group to
minimize these influences.
© 2011 Elsevier Inc. All rights reserved.
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1. Introduction
The blood–brain barrier (BBB) is commonly studied
using dynamic contrast-enhanced MRI (DCE-MRI) in
diseases such as brain tumors [1–3] and multiple sclerosis
[4–6] where a relatively large focally abnormal BBB is
observed. There is increasing interest in using this imaging
technique to identify more subtle BBB abnormalities, such
as those which occur with normal ageing [7], dementia
[7–12], Alzheimer's disease [13], type II diabetes [14],
cerebral microvascular disease [7,15] and in nonenhancing
multiple sclerosis lesions [16,17]. These initial results
suggest that DCE-MRI of subtle BBB disorders may provide
useful information. However, maximum post-contrast signal
differences are small, typically about 5% in gray matter and
1–2% in white matter, with changes over the imaging period
being on the order of 1–2%, and differences between patient
groups on the order of a few percent at most. These results
contrast with conventional DCE-MRI applications where
signal enhancement may be on the order of 100% or greater
in tumors [1,18] and 50% in multiple sclerosis [6].
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The small changes associated with subtle BBB disorders
will be significantly influenced by scanner noise, thereby
requiring large sample sizes to minimize random noise and
identify differences between groups, if present. The effects
of noise on concentration estimation in DCE-MRI have been
extensively investigated by Schabel and Parker [19], but they
do not explicitly present results for the very low concentra-
tions found in subtle BBB abnormalities, although their
methods are equally valid for this situation. Other factors
such as scanner drift and differences in background signal
characteristics of different tissues might also contribute to
observed signal differences and their influences need to be
investigated. Furthermore, all of the DCE-MRI studies
investigating these more subtle BBB disorders have used
relatively simple analytical approaches, typically measuring
signal enhancement over time in brain regions and inferring a
direct relationship to BBB breakdown, i.e., assuming that
greater signal enhancement equates to greater contrast agent
concentration indicating a more abnormal BBB. This is a
somewhat simplistic approach compared with established
methodologies [6] that attempt to model the relationship
between signal, contrast agent concentration and pharmaco-
kinetics in order to quantify BBB abnormalities. In addition
to providing a mechanism for estimating physiological
parameters, the more complex modeling was developed to
control for the effects of background tissue parameters, such
as the pre-contrast longitudinal and transverse relaxation
times (T10 and T20), and the longitudinal and transverse
contrast agent relaxivities (r1 and r2), which affect the
relationship between signal enhancement and contrast agent
concentration. Analytical expressions describing the sensi-
tivity of the signal enhancement–contrast agent concentra-
tion relationship to background tissue parameters have
previously been obtained [19] and demonstrate that the
relationship is nonlinear and dependent on the tissue
parameters, such that the simple linear assumption is
generally invalid. Tofts et al. [20] also performed an error
analysis indicating how uncertainties in the experimental
parameters propagate through to modeled pharmacokinetic
parameters, although the results presented were based on
breast carcinoma and not directly applicable to the low
concentrations associated with mild BBB impairment.
In this work, the aim was to determine to what extent
scanner noise, drift, intrinsic tissue properties (defined by
T10, T20, r1 and r2) and imaging sequence parameters
affect the interpretation of post-contrast signal enhancement
in different tissues and over the range of values relevant to
subtle BBB disorders. DCE-MRI data was acquired from
patients with mild stroke, as part of a larger study
investigating associations between stroke subtype and
background BBB alterations [15]. This patient population
exhibits a range of white matter lesion extent and was
classified according to the degree of white matter
abnormalities present. The DCE-MRI data were analyzed
by conventional assessment of signal enhancement curves
and modeling of contrast agent concentration. Phantom and
volunteer data were obtained to assess the effects of
background scanner noise and drift in different tissues. A
theoretical analysis was performed to identify the effect of
variations in intrinsic tissue and experimental parameters
on the estimation of contrast agent concentration from
signal enhancement.
2. Materials and methods
2.1. MRI Scanning
Sixty patients with mild ischemic stroke, diagnosed by an
experienced stroke physician, underwent MRI. The local
ethics committee approved the study and informed consent
was obtained from all patients. Diagnostic MRI was
performed on all patients, followed by DCE-MRI at least 1
month after the stroke to minimize any acute effect of the
stroke on local BBB changes in the stroke lesion. Imaging
was undertaken on a 1.5T MRI scanner (GE Signa LX,
Milwaukee, WI, USA) with standard quadrature head coil.
The diagnostic MRI was used to establish the recent infarct
site and to classify white matter lesion extent [axial imaging:
diffusion-weighted (TR/TE=9999/98.8 ms, 128×128 matrix,
240×240 mm FOV, 5 mm slice thickness, 1 mm slice gap);
T2-weighted (TR/TE=6300/107 ms, 256×256 matrix,
240×180 mm FOV, 5 mm slice thickness, 1.5 mm slice
gap); fluid attenuated inversion recovery (FLAIR) (TR/
TE=9002/147 ms, 256×256 matrix, 240×240 mm FOV, 5
mm slice thickness, 1.5 mm slice gap); and gradient echo
(T2⁎-weighted) (TR/TE=620/15 ms, flip angle α=20°,
240×180 mm FOV, 256×192 matrix, 5 mm slice thickness,
1 mm slice gap)]. DCE-MRI was performed using a 3D fast
spoiled gradient echo (FSPGR) sequence (TR/TE=8.1/3.2
ms, 240×240 mm FOV, 256×256 matrix, 4 mm slice
thickness). The sequence was run before contrast agent
administration with flip angles of 2° and 12° to facilitate T10
measurement [21–26], and the 12° acquisition was repeated
26 times with a temporal resolution of 69 s following an
intravenous bolus injection of 40 ml gadodiamide (Omnis-
can, GE Healthcare, Chalfont St Giles, UK) into the
antecubital vein. In order to assess scanner drift, the DCE-
MRI protocol was also performed on six healthy volunteers
without administration of contrast agent and on gadodia-
mide-doped water phantoms with T10 values representative
of brain tissue and cerebrospinal fluid (CSF).
2.2. Image analysis
An experienced neuroradiologist examined the T2-
weighted and FLAIR sequences from all patients in detail,
classifying deep and periventricular white matter abnormal-
ities according to the Fazekas scale (range 0 to 3) [27]. The
scores for deep and periventricular abnormalities were
averaged to give an overall Fazekas white matter rating
and patients were dichotomized into those with overall
Fazekas rating b1.5 (low) or ≥1.5 (high).
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The DCE-MRI data were motion corrected by aligning all
FSPGR acquisitions to the pre-contrast 12° acquisition using
computational image realignment [28]. Maps of T10 were
calculated voxel by voxel from the two pre-contrast
acquisitions, Sa and Sb, acquired with flip angles αa=2° and
αb=12° using the formula adapted from Brookes et al. [22]
1
T10
=
1
TR
ln
SR sin ab cos aa − sin aa cos ab
SR sin ab − sin aa
 
ð1Þ
where SR=Sa/Sb. Signal enhancement (Et) maps were
calculated voxel by voxel for each of the 26 post-contrast
time points t, such that Et=(St−S0)/S0, where S0 is the pre-
contrast 12° acquisition. The signal enhancement represents
the fractional signal increase above baseline, such that a value
of 0 represents no post-contrast signal increase and a value of
1 represents a doubling of post-contrast signal. Maps of
contrast agent concentration Ct (in millimolars) were
estimated from Et at each time point by voxel-by-voxel
numerical solution of the formula given in Eq. (2) [29],
Et = exp −r2CtTEð Þ
×
1−exp −P −Qð Þ − cos a2 exp −Pð Þ− exp −2P −Qð Þð Þ
1−exp −Pð Þ − cos a2 exp −P−Qð Þ− exp −2P −Qð Þð Þ
 
−1
ð2Þ
where P=TR/T10 and Q=r1CtTR. This method makes the
standard assumption that the post-contrast changes in R1 and
R2⁎ are linearly related to Ct as determined by the contrast
agent relaxivities r1 and r2.
The primary focus of this study was to measure the
background status of the BBB, rather than alterations caused
by the acute event, and so imaging was performed at least 1
month after stroke onset and measurements taken remotely
from the site of the recent infarct. Multiple small circular
regions of interest (ROIs) of three voxels' diameter were
positioned to sample the calculated T10, Et and Ct maps in
white matter (84 ROIs), cortical gray matter (44 ROIs), deep
gray matter (12 ROIs), CSF (10 ROIs) and major vessels (7
ROIs) on the pre-contrast 12° acquisition, using standard
templates to ensure consistent sampling of brain regions
blind to all other data including knowledge of post-contrast
signal change. If necessary, the template ROI location was
then adjusted slightly to avoid the recently ischemic lesion;
however, ROIs were not adjusted to avoid white matter
lesions. Measurements from all ROIs were combined for
each subject and tissue type to produce overall mean and
standard deviation values for T10, Et and Ct. The mean Et
(Et
ave) and Ct (Ct
ave) were averaged over all post-contrast
time points and along with T10 were averaged over all
patients for each tissue type in each of the high- and low
Fazekas-rated groups, to give overall mean and standard
deviation values for each tissue in each group. A Student's t
test was performed to look for significant differences in T10,
Et
ave or Ct
ave between the low- and high Fazekas-rated groups
in each tissue.
The sensitivity of the FSPGR acquisition to scanner noise
and drift was assessed using data acquired from volunteers
and phantoms, processed in exactly the same way as the
patient data. For the phantom data, ROIs were placed to cover
the phantoms (cylindrical tubes of approximately 2 cm
diameter and 10 cm length), and for volunteer data ROIs were
placed as described above for the patient case. The
contribution to the signal enhancement curves from scanner
noise and drift was obtained by calculating the mean and
standard deviation of Et for each tissue type (or phantom)
over all time points and by analyzing the slope of the signal
enhancement profiles using standard linear regression
analysis performed with the regression function in Microsoft
Excel. These findings were then compared to the patient data.
2.3. Theory and simulation
Errors in the estimation of intrinsic tissue parameters (T10,
T20, r1 and r2) on the calculation of contrast agent
concentration have been extensively studied by Schabel
and Parker [19] who derived analytical expressions for the
relative bias in the concentration measurement resulting from
a biased estimate of the intrinsic tissue parameters. They
demonstrated that T10 produces a negative concentration
bias that has the greatest influence of all the tissue
parameters, r1 also results in a negative concentration bias
but to a lesser degree than T10, while r2 produces a fairly
negligible positive concentration bias, only becoming
significant at very high concentrations. The concentration
estimation is independent of T20 in the fast exchange regime
and so this parameter need not be considered further.
To gain a further insight into whether the small changes in
Et (Et
diff) observed between patient and control populations in
subtle BBB abnormalities could result from a difference in
intrinsic tissue parameters T10 or r1 rather than from a true
difference in contrast agent concentration, a theoretical
analysis was performed based on the data obtained in this
study. Firstly, a representative Et value was obtained for each
tissue by calculating the mean post-contrast Et (Et
ave) across
the entire 30-min imaging period from the group of patients
with low overall Fazekas rating (b1.5). For each tissue, mean
enhancement Et
ave was converted into contrast agent
concentration Ct
ave, with T10 taken as the mean pre-contrast
value in each tissue measured from all low Fazekas-rated
patients and r1 (r2) assumed to be 4.3 (5.2) s
−1 mM−1 in all
tissues [30]. The variation in T10 or r1 required to produce the
Et
diff observed between the low- and high Fazekas-rated
patients in each tissue (see Table 1) was then calculated,
assuming the concentration Ct
ave remained fixed in each
tissue. This procedure estimates the T10 or r1 change that
would be required to cause the mean enhancement difference
observed in subtle BBB breakdown due to white matter
abnormalities, assuming that there is no difference in the
contrast agent concentration between the two patient groups.
A more generic analysis of the effects of T10, r1 and r2 on
measurements of contrast agent concentration can be found
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in Schabel and Parker [19]. This error analysis also enables
calculation of the relative uncertainty in the estimation of
contrast agent concentration ɛrel when varying experimental
parameters such as SNR, flip angle αb and the number of
baseline images Nb. The effect of varying these parameters
was investigated for the relevant concentration range
associated with subtle BBB disorders. The relationship was
explored for T10 and T20⁎ parameters representative of blood,
gray matter, white matter and CSF, while the effect of
varying flip angle αb, number of post contrast measurements
N and number of baseline measurements Nb was explored for
white matter.
Table 1
Summary of Et
ave, Ct
ave and T10 measurements obtained from five tissues with patients grouped by Fazekas white matter lesion ratings
Deep gray Cortical gray White matter CSF Blood
Et
ave Fb1.5 0.064±0.033 0.074±0.027 0.015±0.011 0.167±0.118 1.463±0.408
F≥1.5 0.070±0.033 0.077±0.026 0.018±0.010 0.132±0.091 1.664±0.445
(F≥1.5)–(Fb1.5) 9.15% 4.29% 15.02% −23.68% 12.81%
Ct
ave Fb1.5 0.020±0.012 0.019±0.007 0.009±0.004 0.009±0.009 0.779±0.315
F≥1.5 0.020±0.008 0.019±0.006 0.009±0.004 0.007±0.009 0.968±0.325
(F≥1.5)–(Fb1.5) −3.07% 0.37% −2.21% −23.95% 21.62%
T1 Fb1.5 1150±90 1259±78 787±78 5592±683 1486±431
F≥1.5 1185±99 1266±84 849±74 5555±785 1346±336
(F≥1.5)–(Fb1.5) 2.97% 0.58% 7.57% −0.66% −9.84%
Fig. 1. Signal enhancement (A and B) and estimated contrast agent concentration (C and D) uptake profiles obtained from blood, CSF, cortical gray matter, deep
gray matter and white matter ROIs in 60 stroke patients, 32 with low overall Fazekas ratings (b1.5) and 28 with high overall Fazekas ratings (≥1.5). (A) and (C)
are scaled to illustrate the blood signal relative to the other tissues, while (B) and (D) illustrate the tissue signals only. It is clear that any analysis of contrast agent
uptake profiles would depend significantly on whether signal enhancement or modeled contrast agent concentration data was used.
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3. Results
3.1. Patient data
Fig. 1 illustrates the average temporal evolution of Et and
Ct obtained from the 60 stroke patients (mean±S.D. age:
67±12 years; time from stroke onset: 68±36 days), 32 with
low Fazekas rating and 28 with high rating, and Table 1
summarizes Et
ave and Ct
ave measurements for each tissue. As
expected, the blood signal enhances the most with Et
ave≈1.5,
which is approximately 20 times greater than either cortical
gray matter (Et
ave≈0.08) or deep gray matter (Etave≈0.07).
White matter enhances the least with Et
ave≈0.02, and
CSF enhances by about double that of gray matter with
Et
ave≈0.15. The relationship between tissues is noticeably
altered when contrast agent concentration is considered. In
this case, blood signal again has the highest estimated
concentration with Ct
ave≈0.8 mM, which is roughly 40 times
greater than cortical or deep gray matter which both have
Ct
ave≈0.020 mM, and white matter remained the lowest of
the brain tissues with Ct
ave≈0.009 mM. However, the
relative difference between white and gray matter was
reduced when converting from signal enhancement to
contrast agent concentration. The most marked difference
was in the CSF where the estimated concentration was the
lowest of all tissues with Ct
ave≈0.008 mM. All tissues
exhibit similar temporal trends, rising to a maximum by the
second post-contrast time point and then gradually falling
over time, except for CSF, which rose more progressively
over time. The mean T10 values for all patients were
estimated to be 1421 ms (blood), 1262 ms (cortical gray
matter), 1166 ms (deep gray matter), 816 ms (white matter)
and 5575 ms (CSF). The last value is significantly
overestimated with the current two-flip-angle FSPGR
acquisition protocol and will lead to an underestimation in
the CSF concentration.
No significant differences were observed for Et
ave or Ct
ave
between high- and low Fazekas-rated groups in any tissues,
although there was a trend towards greater Et
ave in the high
Fazekas-rated group in brain tissues. For T10, the white
matter measurement was significantly longer in the high
Fazekas-rated than in the low Fazekas-rated groups
(P=.003); a trend towards longer T10 in gray matter in the
high Fazekas-rated group was observed, while both CSF and
blood T10 were generally shorter in this group (P=ns).
Therefore, in gray and white matter, these T10 differences
explain the lower relative difference between patients with
high and low Fazekas scores when interpreted using Ct data
rather than using Et. Similarly, the differences in blood and
CSF between the two groups explain the slightly greater
difference observed in Ct, rather than in Et.
3.2. Scanner noise and drift
Table 2 illustrates the mean and standard deviation of
Et
ave for measurements obtained from phantoms with T10
values of 980 ms (brain tissue equivalent) and 2800 ms (CSF
equivalent), six noncontrast volunteers (mean±S.D. age:
33±4 years) and all 60 stroke patients. Also tabulated are the
slope, R2 and P value obtained from performing standard
linear regression analysis on the data. The phantom and
volunteer data indicate that scanner drift is generally well
controlled on our system with a slight upward drift in signal
being observed. To put these results into context, they can
also be described in terms of the measured signal values. The
typical signal enhancement equivalent to a change of one
signal unit was measured by estimating the mean baseline
signal (S0) in each tissue. The baseline signal values were 58,
52, 64, 20 and 44 for deep gray matter, cortical gray matter,
white matter, CSF and blood, respectively, giving signal
enhancement equivalent to one signal unit (i.e., 1/S0) of
0.017, 0.019, 0.016, 0.050 and 0.023, respectively. For brain
tissue, Table 2 indicates that scanner drift and noise are well
within a single signal unit in both volunteers and the
phantom equivalent. For CSF, the drift was slightly greater,
reaching a maximum of around 1.5 signal units after 30 min
in the volunteer data and around 1 signal unit in the phantom
data. For the patient data, with administered contrast agent,
the mean post-contrast signal enhancement is equivalent to
about 4 signal units in gray matter, 1 in white matter, 3 in
CSF and 64 in blood, with changes over the imaging period
following the first post-contrast time point being around −1.3
in gray matter, −0.5 in white matter, 2.2 in CSF and −15 in
blood. These small signal differences will be influenced by
discretization errors, as the signal is sampled as integer
values. However, as the contrast agent uptake curves are
obtained by averaging data from many voxels, these effects
are expected to largely cancel out. Simulations performed
based on the data obtained in this study indicate that the
discretization error for white matter would be less than
0.01% for data averaged from 1000 voxels, far fewer than
that used to generate the curves in Fig. 1. Nevertheless, if the
ultimate aim is to compare data on a voxel-by-voxel basis,
then discretization errors need to be reduced, possibly by
improving scanner electronics or the procedure used for
setting the receiver gain.
Table 2
Average post-contrast signal enhancement E t
ave and linear regression
analysis results from phantoms, healthy volunteers and 60 mild stroke
patients
Tissue E t
ave Slope R2 P value
Phantom T1=982 ms 0.001±0.004 0.00005 0.01 .61
T1=2800 ms 0.012±0.061 0.00137 0.74 b.01
Volunteer Deep gray matter −0.006±0.003 0.00009 0.05 .27
Cortical gray matter 0.001±0.004 0.00031 0.57 b.01
White matter −0.007±0.002 −0.00001 0.00 .86
CSF 0.115±0.030 0.00250 0.55 b.01
Blood 0.013±0.005 0.00045 0.54 b.01
Patient Deep gray matter 0.076±0.026 −0.00073 0.79 b.01
Cortical gray matter 0.067±0.033 −0.00072 0.89 b.01
White matter 0.016±0.010 −0.00033 0.87 b.01
CSF 0.150±0.107 0.00369 0.97 b.01
Blood 1.557±0.433 −0.01124 0.49 b.01
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3.3. Theory and simulation
The theoretical analysis demonstrated that to cause a
greater signal enhancement for a given contrast agent
concentration, either T10 or r1 must be increased. The
9.15% increase observed in deep gray matter Et
ave between
high- and low Fazekas-rated patients would require the
baseline T10 to be increased by 86 ms in the high Fazekas-
rated group compared to the low Fazekas-rated group. While
this is greater than the 35-ms increase observed, it is within
experimental error. Similarly, the observed differences
between high- and low Fazekas-rated groups in cortical
gray matter, white matter, CSF and blood Et
ave of 4.29%,
15.02%, −23.68% and 12.81% would require T10 to differ by
43, 81, −1092 and 180 ms, respectively. The observed mean
T10 differences in each of these tissues are 7, 62, −37 and
−140 ms, which, while being consistently lower in
magnitude than that required to cause the observed
enhancement differences, are generally within experimental
error of the simulated values due to the large error associated
with these measurements. Similarly, if a difference in r1
between high- and low Fazekas-rated patients were to be
responsible for the differences in Et
ave, then r1 would need to
be altered from its assumed value of 4.3 s−1 mM−1 by 0.43,
0.20, 0.94, −0.93 and 1.04 s−1 mM−1 in each of deep gray
matter, cortical gray matter, white matter, CSF and blood,
respectively. These changes are equivalent to 9.6%, 4.4%,
20.9%, −20.7% and 23.1% deviations from the assumed r1
in each of the respective tissues. These simulated data
suggest that the signal enhancement differences seen in this
study of 0.003 in cortical gray and white matter, 0.006 in
deep gray matter and 0.035 in CSF could potentially result
from differences in background tissue T10 or r1, as the
predicted values are not unfeasibly large and usually lie
within experimental error of the observed differences.
Fig. 2A illustrates the relative uncertainty in the
estimation of contrast agent concentration (ɛrel) as a function
of the concentration (Ct) for blood, gray matter, white matter
and CSF. The relationship assumes FSPGR sequence
parameters as described in the MRI Scanning section with
Fig. 2. Calculated percentage error in the concentration estimation, ɛ rel (%), as a function of the concentration, Ct, plotted for different tissues (A); flip angles, αb
(B); post-contrast measurements, N (C); and number of baseline pre-contrast measurements, Nb (D).
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a flip angle αb=12°, a constant SNR=8 for all tissues and
T10/T20⁎ values of 1441/290 ms for blood, 1000/49 ms for
gray matter, 750/68 ms for white matter and 3000/1500 ms
for CSF [19,31]. The figure clearly demonstrates that the
concentration estimation error greatly increases for concen-
trations typical of those measured in this study, i.e., Ctb0.2
mM. The largest error occurs in white matter, where for
typical concentrations of 0.01 mM, ɛrel=681%. Fig. 2B
demonstrates that the flip angle used in this study is well
optimized for low concentration measurements in white
matter, as increasing the flip angle leads to increased ɛrel at
lower concentrations, albeit with slightly reduced error at
high concentrations. Increasing the flip angle results in errors
of 782% at 16°, 911% at 20° and 1053% at 24°, compared to
681% at 12° for Ct=0.01 mM in white matter. Reducing the
flip angle does slightly improve the measurement error at
low concentration; a flip angle of 8° reduces the error at 0.01
mM from 681% to 663%, but at the expense of a
considerably poorer performance at high concentrations.
Fig. 2C demonstrates that a considerable reduction in ɛrel can
be achieved by increasing the number of post-contrast
measurements (equivalent to increasing the SNR of the
experiment); however, around 10,000 measurements are
required to reduce ɛrel to a reasonably acceptable 7%, if it is
assumed that the SNR increases in proportion to √N. Finally,
Fig. 2D demonstrates that modest reductions in ɛrel can also
be obtained by increasing the number of baseline pre-
contrast measurements, reducing ɛrel from 681% for Nb=1,
587% for Nb=2 and 500% for Nb=10, provided that scanning
time constraints and patient compliance allow.
4. Discussion
Fig. 1 and Table 1 indicate that post-contrast signal
enhancement measured in mild stroke patients is small,
ranging from less than 2% in white matter, 8% in gray
matter, to 16% in CSF. When comparing measurements
between the high- and low Fazekas-rated patients, relatively
large differences were observed by imaging study standards,
i.e., as high as 24% in CSF for Et
ave and Ct
ave, so it is
somewhat disappointing that these differences did not reach
statistical significance. The reason for this is due to the
small absolute enhancement relative to noise, resulting in a
large variance in the measurements, as illustrated in Table 1.
Percentage coefficients of variation (100×S.D./mean) aver-
aged over all tissues were 13% for T1, 49% for Et
ave and
56% for Ct
ave, indicating that the T10 measurement is
reasonably precise, while those of Et
ave and Ct
ave are
considerably less so.
The theoretical error analysis demonstrated that around
10,000 measurements were required in order to reduce the
concentration measurement error ɛrel to around 7% in white
matter. In the experimental setup used in this study with 84
white matter ROIs of size nine voxels, 756 white matter
voxels were measured per patient and therefore data from
around 13 patients would be required to achieve a 7% error.
Given that the individual voxel measurements are not
independent, it is unlikely that the SNR will scale perfectly
by √N, but these theoretical findings fit reasonably well with
our empirical observation that the contrast agent uptake
curves become reasonably smooth and consistent after
around 20 patients, although many more patients may be
required to detect very small differences. The experimental
setup appears to be well optimized with regard to flip angle
choice, but future studies could benefit by acquiring
additional pre-contrast baseline measurements, as indicated
in Fig. 2D.
Some of the variance introduced in the measurements of
Et
ave and Ct
ave will result from the use of a constantly
administered contrast agent volume resulting in different
doses being administered to different patients. The average
mass of the patients was 76±15 kg (mean±S.D.), i.e., a
coefficient of variation of 20%, with the average mass of the
high Fazekas-rated patients being 13% lower than that of the
low Fazekas-rated patients. Therefore, the more abnormal
patients would have received a slightly higher contrast agent
dose which appears to be reflected in the measured blood
Et
ave and Ct
ave. Clearly, future studies should use a constant
contrast agent dose for all patients if signal enhancement or
contrast agent concentration curves are going to be analyzed
to avoid potentially erroneous conclusions being made.
The strong influence of noise is clearly evident when
comparing the patient data with measurements obtained in
phantom and volunteer data with no administered contrast
agent. With the exception of the blood measurements, the
differences between high- and low Fazekas-rated patients
(Table 1) are comparable in magnitude to the standard
deviation of the measurements obtained in the phantom and
volunteer data with no administered contrast agent (Table 2).
Scanner drift appears to be reasonably well controlled in
all tissues except for CSF, as the post-contrast signal changes
in patients are generally an order of magnitude greater than
those observed in the phantom and volunteer cases.
Furthermore, the small amount of drift observed in phantoms
and volunteers generally opposes the trend observed in
patients with contrast agent administered. However, in CSF,
drift measured in phantoms and volunteers was of compa-
rable magnitude to that observed post-contrast in patients,
suggesting that scanner drift may significantly influence the
enhancement profiles observed in CSF. This raises the issue
of how to perform a correction because our data indicate that
the degree of drift is dependent on the tissue type, suggesting
that a simple correction based on a single phantom may not
be sufficient. Furthermore, the drift itself is small, so
measurements will be influenced by noise and likely difficult
to reliably estimate for correction of an individual patient's
data set. Therefore, scanner drift may introduce tissue-
dependent systematic deviations in signal enhancement
profiles, which, on our system, are particularly noticeable
for higher T10 values, such as those found in CSF. It is
possible that CSF flow influences the in vivo measurements,
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but at present we do not have an explanation for the
differential drift observed in phantoms.
Converting signal enhancement profiles to contrast agent
concentration noticeably altered the relationships between
the different tissues for both subject groups. This arises due
to the difference in T10 values between tissues and the
nonlinear relationship between enhancement and concentra-
tion given by Eq. (2) and clearly illustrated in Fig. 2 of
Schabel and Parker [19]. These results demonstrate that it is
dangerous to assume that signal enhancement consistently
relates to the amount of contrast agent present in any given
tissue, compared to others, when those tissues differ in their
intrinsic parameters T10 or r1. This emphasizes the
importance of selecting an appropriate control group, with
a view to minimizing these differences. Similarly, comparing
the same tissue in a normal state and differing degrees of
disease will not be consistently represented by signal
enhancement, if T10 or r1 is altered during the disease
process. Thus, a change in T10 or r1 either as part of, or
associated with, the disease process can affect the changes
observed in signal enhancement. For example, in addition to
increased leakage of contrast agent, a common consequence
of BBB breakdown is an increase in tissue water content.
This elevated water content will lead to local changes in T10
and r1 that alter the observed signal enhancement, in
addition to the change resulting from increased contrast
agent concentration. Previous work suggests that T10 would
be elevated in tissue with greater water content, while r1 is
related to tissue solids content and reduces in tissue with
greater water content [32,33]. The enhancement–concentra-
tion relationship defined by Eq. (2) indicates that these
would produce opposing effects, with increased T10 leading
to greater signal enhancement and reduced r1 leading to
lower signal enhancement in tissue with greater water
content. Therefore, when signal enhancement is interpreted,
it is not possible to know whether enhancement differences
are due to a true difference in contrast agent concentration or
to differences in T10 and/or r1. Using a model, such as that
proposed in Eq. (2), to calculate contrast agent concentration
attempts to overcome these limitations, provided that T10
and r1 can be reliably estimated for all tissues.
Unfortunately, it is not straightforward to measure either
of the tissue parameters, T10 or r1, in the clinical setting
with a high degree of reliability over the full range of values
found in the brain. For example, while providing a relatively
fast measurement, the two flip angle T10 measurement
procedure used in this work overestimated T10 at greater
values, most notably in CSF. This overestimation only
results in a modest underestimation of Ct, but if accurate
CSF measurements are required, the T1 measurement
procedure should be improved, while still maintaining a
clinically acceptable imaging time. Reliable estimation of r1
is even more challenging, and a significant weakness of
current DCE-MRI methodologies is the reliance on an
assumed in vitro value for the r1 relaxivity. This is despite
relaxivity measurements being known to vary significantly
between (ex vivo) tissue samples measured thus far,
although at least the relaxivity appears to consistently
describe a linear relationship between reciprocal T1 change
and contrast agent concentration at all but the most extreme
concentrations [33–37]. However, as a feasible method for
direct measurement of contrast agent concentration in living
human tissue remains elusive, relaxivity properties of in
vivo brain tissues (whether normal or diseased) remain
largely unknown.
While the influence of T10 and r1 on the interpretation of
signal enhancement curves is potentially significant, their
effects are frequently ignored, particularly in the case of r1.
This has been accepted in the community because traditional
applications of DCE-MRI in tumors and MS produce very
large signal enhancement, compared to normal tissues or
subtle BBB disorders. Therefore, it is likely that such
changes do arise from significant contrast agent uptake rather
than from T10 or r1 alterations which would have to change
by unfeasibly large amounts. Furthermore, when the
enhancement is so great, there is a lesser requirement to
measure T10 or r1 to such a high degree of accuracy, as small
errors are unlikely to alter the overall conclusion, even
though more subtle differences may be lost. In contrast, for
subtle BBB disorders exhibiting small enhancement differ-
ences, relatively small differences in T10 or r1 could radically
alter the conclusions drawn. As a result, T10 or r1 really
needs to be known with a high degree of accuracy and
accounted for when interpreting DCE-MRI results in subtle
BBB disorders.
This work has described the limitations of directly
inferring contrast agent concentration from signal enhance-
ment curves in the context of subtle BBB disorders.
However, it should be noted that even if a reliable estimation
of contrast agent concentration profiles in each tissue is
obtained, it is only a first step towards obtaining a
quantitative estimate of BBB disruption. Unfortunately,
MR-based measurements originate from relatively large
voxels containing several different tissues or cellular
environments, making it difficult to separate the contribution
from each biological compartment. This is particularly
important for tissues with high blood volume as this can
make a particularly large contribution to the estimated
concentration. In practice, pharmacokinetic modeling is used
to relate the contrast agent concentration in the different
compartments to underlying physiological parameters.
While such models have been applied to DCE-MRI data of
tumors and multiple sclerosis [6], none has modeled
exchange to and from the CSF, which may be necessary in
more subtle disorders [14]. Statistical modeling has also been
employed, but great care is required to ensure that parameters
are adequately modeled between tissues. Further work is
required to establish whether these complex models can be
supported by the data generated from DCE-MRI studies of
subtle BBB disorders. It may be that other contrast agents
need to be investigated with the aim of increasing the signal
enhancement compared to that from gadodiamide, or scanner
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electronics and gain setting improved to increase the
dynamic range of signal capture and reduce the influence
of noise and signal discretization error. However, if the
ultimate goal is to establish whether differences in
concentration profiles are truly reflective of endothelial
permeability in subtle disorders, then a quantitative assess-
ment is required and these problems need to be overcome.
5. Conclusion
DCE-MRI was performed on a group of mild stroke
patients classified into two groups using the Fazekas white
matter rating scale. No significant differences were found
between patients with a high or low white matter rating,
although there was a trend towards greater enhancement in
patients with a higher degree of white matter abnormality.
The effect of noise, scanner drift, intrinsic tissue parameters
and imaging sequence parameters on the interpretation of the
signal enhancement profiles was assessed. Background
noise was found to be comparable in magnitude to the
observed differences, while scanner drift had less influence
except in the CSF where a progressive rise in signal was
observed. Calculation of contrast agent concentration,
correcting for systematic differences in intrinsic tissue
parameters, noticeably altered the relationship between
tissues when compared to signal enhancement measure-
ments, although differences between patient groups
remained insignificant. These results suggest that it may be
inappropriate to draw conclusions about the amount of
contrast agent present in a tissue, and hence it is likely BBB
impairment, from signal enhancement data. Therefore,
studies of subtle BBB abnormalities should establish the
influence of noise, drift and intrinsic tissue parameters on
their data before conclusions are drawn. If this is not done,
systematic errors introduced by drift and intrinsic tissue
parameters may be erroneously perceived as BBB differ-
ences between patients. Careful selection of a control
population may help to compensate for these issues,
provided that the parameters that influence signal enhance-
ment are expected to be identical between the control and
study populations. Nevertheless, it is clear that present
acquisition and processing methodologies are some way off
enabling a reliable quantitative assessment of subtle BBB
abnormalities and further work is required to improve these.
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